Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Targeting of PI3K/AKT signaling and DNA damage response in acute myeloid leukemia: a novel therapeutic strategy to boost chemotherapy response and overcome resistance

Publikation: Bidrag til tidsskriftReviewForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{1bd9d90d79aa40b38865af55ee8d4c91,
title = "Targeting of PI3K/AKT signaling and DNA damage response in acute myeloid leukemia: a novel therapeutic strategy to boost chemotherapy response and overcome resistance",
abstract = "Resistance of cancer patients to DNA damaging radiation therapy and chemotherapy remains a major problem in the clinic. The current review discusses the molecular mechanisms of therapy resistance in acute myeloid leukemia (AML) conferred by cooperative chemotherapy-induced DNA damage response (DDR) and mutational activation of PI3K/AKT signaling. In addition, strategies to overcome resistance are discussed, with particular focus on studies underpinning the vast potential of therapies combining standard chemotherapy AML regimens with small molecule inhibitors targeting key regulatory hubs at the interface of DDR and oncogenic signaling pathways.",
keywords = "AML, Chemotherapy, DNA damage response, PI3K/AKT, Resistance",
author = "Alrich, {Montserrat Estruch} and Camilla Vittori and Teresa Mu{\~n}os-Montesinos and Kristian Reckzeh and Kim Theilgaard-M{\"o}nch",
year = "2021",
month = nov,
day = "10",
doi = "10.20517/cdr.2021.76",
language = "English",
volume = "4",
pages = "984--995",
journal = "Cancer Drug Resistance",
issn = "2578-532X",
publisher = "OAE Publishing",
number = "4",

}

RIS

TY - JOUR

T1 - Targeting of PI3K/AKT signaling and DNA damage response in acute myeloid leukemia: a novel therapeutic strategy to boost chemotherapy response and overcome resistance

AU - Alrich, Montserrat Estruch

AU - Vittori, Camilla

AU - Muños-Montesinos, Teresa

AU - Reckzeh, Kristian

AU - Theilgaard-Mönch, Kim

PY - 2021/11/10

Y1 - 2021/11/10

N2 - Resistance of cancer patients to DNA damaging radiation therapy and chemotherapy remains a major problem in the clinic. The current review discusses the molecular mechanisms of therapy resistance in acute myeloid leukemia (AML) conferred by cooperative chemotherapy-induced DNA damage response (DDR) and mutational activation of PI3K/AKT signaling. In addition, strategies to overcome resistance are discussed, with particular focus on studies underpinning the vast potential of therapies combining standard chemotherapy AML regimens with small molecule inhibitors targeting key regulatory hubs at the interface of DDR and oncogenic signaling pathways.

AB - Resistance of cancer patients to DNA damaging radiation therapy and chemotherapy remains a major problem in the clinic. The current review discusses the molecular mechanisms of therapy resistance in acute myeloid leukemia (AML) conferred by cooperative chemotherapy-induced DNA damage response (DDR) and mutational activation of PI3K/AKT signaling. In addition, strategies to overcome resistance are discussed, with particular focus on studies underpinning the vast potential of therapies combining standard chemotherapy AML regimens with small molecule inhibitors targeting key regulatory hubs at the interface of DDR and oncogenic signaling pathways.

KW - AML

KW - Chemotherapy

KW - DNA damage response

KW - PI3K/AKT

KW - Resistance

UR - http://www.scopus.com/inward/record.url?scp=85123370145&partnerID=8YFLogxK

U2 - 10.20517/cdr.2021.76

DO - 10.20517/cdr.2021.76

M3 - Review

C2 - 35582388

VL - 4

SP - 984

EP - 995

JO - Cancer Drug Resistance

JF - Cancer Drug Resistance

SN - 2578-532X

IS - 4

ER -

ID: 71682101